Your browser doesn't support javascript.
loading
Biomarkers for response to TIL therapy: a comprehensive review.
Albarrán Fernández, Víctor; Ballestín Martínez, Pablo; Stoltenborg Granhøj, Joachim; Borch, Troels Holz; Donia, Marco; Marie Svane, Inge.
Affiliation
  • Albarrán Fernández V; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Ballestín Martínez P; Ramón y Cajal University Hospital, Department of Medical Oncology, Madrid, Spain.
  • Stoltenborg Granhøj J; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Borch TH; Clínico San Carlos University Hospital, Department of Medical Oncology, Madrid, Spain.
  • Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Marie Svane I; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
J Immunother Cancer ; 12(3)2024 Mar 13.
Article in En | MEDLINE | ID: mdl-38485186
ABSTRACT
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8CD4 ratio, ex vivo culture time, expression of exhaustion markers, costimulatory signals, antitumor reactivity, and scope of target tumor-associated antigens), and other treatment-related factors (such as lymphodepleting chemotherapy and postinfusion administration of interleukin-2).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphocytes, Tumor-Infiltrating / Melanoma Limits: Humans Language: En Journal: J Immunother Cancer Year: 2024 Document type: Article Affiliation country: Denmark

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphocytes, Tumor-Infiltrating / Melanoma Limits: Humans Language: En Journal: J Immunother Cancer Year: 2024 Document type: Article Affiliation country: Denmark